Celularity Welcomes Richard J. Berman to Board of Directors
![Celularity Welcomes Richard J. Berman to Board of Directors](https://investorshangout.com/images/blog/ihnews-Celularity%20Welcomes%20Richard%20J.%20Berman%20to%20Board%20of%20Directors.jpg)
Celularity Appoints Richard J. Berman to the Board
Celularity Inc. (NASDAQ: CELU), a forward-thinking regenerative and cellular medicine company specializing in placental-derived allogeneic cell therapies and advanced biomaterial products, has announced the appointment of Richard J. Berman to its Board of Directors. Mr. Berman is a seasoned public company director, with over 40 years of experience in venture capital, senior management, and mergers and acquisitions. His extensive knowledge includes directing public and private companies, six of which have surpassed one billion dollars in market value within the last five years.
Mr. Berman's Extensive Background
Throughout his distinguished career, Mr. Berman held notable positions at prestigious firms such as Goldman Sachs, and as Senior Vice President at Bankers Trust Company, he pioneered the M&A Leveraged Buyout Departments. His impressive track record includes advising on over $4 billion in merger and acquisition transactions, successfully completing more than 300 deals. This extensive experience will be invaluable to Celularity as it seeks to enhance its strategic growth trajectory.
Leadership Insights from Celularity
Robert J. Hariri, M.D., Ph.D., the founder, Chairman, and Chief Executive Officer of Celularity, expressed enthusiasm about Mr. Berman’s appointment. He stated, “I am pleased to welcome Richard Berman to the Celularity Board of Directors, to which he brings a unique depth of experience and leadership guiding public companies and helping them build and execute growth plans.”
Mr. Berman's Vision for Celularity
In light of his new role, Mr. Berman remarked, “I look forward to working with Dr. Hariri and his team at Celularity as it executes the Company’s focused and disciplined growth plan.” His commitment to innovation and strategic growth aligns with Celularity's mission to deliver cutting-edge regenerative therapies.
About Celularity Inc.
Celularity Inc. (NASDAQ: CELU) is a trailblazer in the field of regenerative and cellular medicine. The company is dedicated to developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies. What distinguishes Celularity from its competitors is its focus on therapeutic programs targeting aging-related diseases, including degenerative diseases, cancer, and immune disorders. This is achieved through the utilization of mesenchymal-like adherent stromal cells (MLASCs), CAR T-cells, and both genetically modified and unmodified natural killer (NK) cells.
Innovative Therapeutic Solutions
By harnessing the unique properties of placental biology, Celularity aims to develop effective, accessible, and affordable therapies addressing significant unmet medical needs. The company's commitment is toward not just advancing treatment options, but also ensuring these solutions are available for a broader range of patients.
Investor and Media Contact Information
Investor Contact:
Carlos Ramirez
Senior Vice President, Celularity Inc.
Email: Carlos.ramirez@celularity.com
Media Contact:
Raquel Cona / Michaela Fawcett
KCSA Strategic Communications
Email: rcona@kcsa.com / mfawcett@kcsa.com
Frequently Asked Questions
Who is Richard J. Berman?
Richard J. Berman is a seasoned director with over 40 years of experience in venture capital and mergers and acquisitions, recently appointed to the Board of Directors of Celularity Inc.
What role will Mr. Berman play at Celularity?
As a board member, Mr. Berman will contribute his extensive expertise in guiding the company’s strategic growth plans and overall direction.
What is the primary focus of Celularity?
Celularity focuses on developing placental-derived allogeneic cell therapies and advanced biomaterial products targeting aging-related diseases and immune disorders.
What are MLASCs in relation to Celularity?
Mesenchymal-like adherent stromal cells (MLASCs) are one of the key cell types being used by Celularity in their regenerative medicine therapies.
How can I contact Celularity for more information?
For investor inquiries, you can reach Carlos Ramirez at Carlos.ramirez@celularity.com. For media inquiries, contact Raquel Cona or Michaela Fawcett at rcona@kcsa.com or mfawcett@kcsa.com, respectively.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Ford Motor Co.'s Shift in Diversity Initiatives Amidst Backlash
- Metagenomi Joins Upcoming Investor Conferences to Share Insights
- Nvidia's Impressive Growth in AI Driving Stock Surge
- Southwestern Law School Partners to Enhance Legal Training
- Impact of Financial Automation on Employee Retention
- Par Pacific Holdings to Attend Key Investor Conferences
- TC Energy Completes $7.9 Billion Notes Offering Success
- ARHT Media Initiates Strategic Review of Operations
- Market Updates: Technology Stocks Struggle Amid Earnings Reports
- HII Welcomes Labor and Navy Secretaries for Workforce Development